Home Ingredients Beta-Sitosterol
CardiovascularMen's HealthKidney/Urinary TractProstate Health

Beta-Sitosterol

Evidence Level
Strong
4 Clinical Trials
7 Documented Benefits
4/5 Evidence Score

Beta-sitosterol is the most abundant plant sterol (phytosterol) in the human diet — structurally similar to cholesterol with an added ethyl group. Found in vegetable oils, nuts, seeds, avocados, whole grains, legumes, and saw palmetto berries. Two distinct clinical applications use very different doses: BPH symptom improvement at 60-130 mg/day, and cholesterol reduction at 1.5-3 g/day plant sterol blends. The BPH evidence is genuinely strong — a Cochrane review of 4 randomized trials in 519 men found significant improvements in urinary symptoms and peak urinary flow versus placebo. The cholesterol reduction effect (6-15% LDL drop) is well-established at the biomarker level, though European cardiovascular societies removed plant sterols from formal cardiovascular recommendations in 2025 due to lack of outcome trial data. One of the four classic phytotherapy components for BPH alongside saw palmetto, pygeum, and stinging nettle root. The honest framing: real BPH symptom relief at low doses; real LDL reduction at high doses; the cardiovascular outcome data isn't there to justify pharmaceutical-level claims.

Studied Dose BPH: 60-130 mg/day (typically 20 mg three times daily). Cholesterol reduction: 1.5-3 g/day plant sterol blend taken with meals. Take with food for absorption.
Active Compound Beta-sitosterol (24-ethyl cholesterol)

Benefits

BPH symptom improvement (Cochrane-level evidence)

A Cochrane review of 4 randomized trials in 519 men found beta-sitosterol significantly improved urinary symptoms and peak urinary flow versus placebo. Foundational evidence: a 6-month trial in 200 men at 60 mg/day showed substantial IPSS improvement and peak flow increase. Prostate volume didn't change — symptom relief comes from functional rather than structural effects.

Supported by Trial 1, Trial 2

Sustained effect at 18 months

Follow-up evidence in men continued from the foundational trial showed symptom improvements maintained over 18 months of continued beta-sitosterol use. Adverse events remained low. Useful for chronic BPH management where long-term safety matters.

Supported by Trial 3, Trial 1

Cholesterol reduction (LDL 6-15%)

Plant sterols including beta-sitosterol reduce LDL cholesterol by competing with cholesterol for absorption at the NPC1L1 transporter — the same target as ezetimibe. Effective doses are 1.5-3 g/day of total plant sterols, taken with meals. FDA-recognized health claim. Note: European cardiovascular guidelines removed plant sterols from formal recommendations in 2025 citing absence of outcome trials despite the biomarker effects.

Supported by Trial 4

Stronger BPH evidence than saw palmetto

A 2024 Cochrane review found saw palmetto no better than placebo for BPH — yet beta-sitosterol is one of saw palmetto's active fractions. Beta-sitosterol monotherapy trials consistently show symptom improvement. Concentrated beta-sitosterol may explain why some saw palmetto preparations work and others don't.

Supported by Trial 2

Combined prostate phytotherapy

Beta-sitosterol is one of four classic BPH phytotherapy ingredients alongside saw palmetto, pygeum, and stinging nettle root. Many commercial prostate formulas combine these components. Additive rather than synergistic effects in available evidence; combination products are reasonable but not clearly superior to single-ingredient supplementation.

Supported by Trial 2

Sitosterolemia contraindication

Sitosterolemia is a rare genetic disorder (roughly 1 in 5 million) caused by ABCG5/ABCG8 mutations — patients absorb plant sterols at very high rates and develop premature severe cardiovascular disease. Plant sterol supplementation is contraindicated in sitosterolemia. Standard population is unaffected; family history of premature cardiovascular disease with elevated plant sterols warrants genetic testing.

Supported by Trial 4

Reduced fat-soluble vitamin absorption (high doses)

High-dose plant sterol supplementation in the cholesterol-reducing range reduces beta-carotene absorption by roughly 25%, with smaller reductions in vitamins A, D, E, and K. Practical impact is modest for typical mixed diets. Lower doses used for BPH are unlikely to meaningfully affect fat-soluble vitamin status.

Supported by Trial 4

Mechanism of action

1

Cholesterol absorption competition (NPC1L1)

Plant sterols competitively inhibit cholesterol uptake at the NPC1L1 transporter in intestinal enterocytes — the same molecular target as ezetimibe. Plant sterols themselves are very poorly absorbed (~5% vs. cholesterol's ~50%) thanks to active efflux by ABCG5/ABCG8 transporters back into the lumen. Net effect: less cholesterol crosses into circulation, more is excreted in feces.

2

5α-reductase modulation (modest)

Beta-sitosterol exhibits modest 5α-reductase inhibition (Cabeza et al. 2003 in hamster prostate). Magnitude is much smaller than finasteride; likely contributes to BPH symptom improvement without producing the systemic DHT depression and sexual side effects of pharmaceutical 5-ARIs.

3

Anti-inflammatory and aromatase modulation

Beta-sitosterol reduces prostaglandin synthesis and modulates aromatase activity (the enzyme converting androgens to estrogens). Both mechanisms likely contribute to prostate symptom relief beyond the modest 5α-reductase effect.

4

Why prostate volume doesn't change but symptoms do

BPH symptoms reflect prostatic obstruction plus bladder detrusor dysfunction plus smooth muscle tone in prostate/bladder neck. Beta-sitosterol's symptom improvement without volume reduction parallels the alpha-blocker mechanism (relax smooth muscle) more than the 5-ARI mechanism (shrink gland). Likely a multi-target phytochemical effect.

Clinical trials

1
Foundational BPH Clinical Trial

German Beta-sitosterol Study Group.

200 men with symptomatic BPH

German Beta-sitosterol Study Group. 200 men with symptomatic BPH randomized to 20 mg beta-sitosterol TID (60 mg/day total) or placebo for 6 months. Primary endpoint: modified Boyarsky score; secondary: IPSS, peak urine flow, prostate volume. Beta-sitosterol significantly improved symptoms and peak flow vs. placebo. Prostate volume unchanged. Adverse events comparable to placebo.

2
Cochrane Review (Cochrane Database Syst Rev CD001043)

Same Minneapolis VA group that produced the pygeum and saw palmetto Cochrane reviews.

519 men

Same Minneapolis VA group that produced the pygeum and saw palmetto Cochrane reviews. 4 clinical trials in 519 men. Pooled effect: significant urinary symptom score improvement (WMD favoring beta-sitosterol) and peak urinary flow improvement (~3.91 mL/s WMD). No effect on prostate volume. Dose range 60-195 mg/day. Authors note standardized dose and preparation not clearly established.

3
18-Month Follow-Up

117 of original 200 participants continued in open-label extension.

200 participants

117 of original 200 participants continued in open-label extension. Symptom improvements maintained over 18 months. Long-term tolerance excellent. One of the longest beta-sitosterol BPH trials available.

4
Plant Sterol Cholesterol Evidence Syntheses

Ras 2014 (Br J Nutr 112:214-219) pooled analysis of 124 trials: ~9-10% LDL reduction at 2 g/day plant sterols.

124 trials pooled

Ras 2014 (Br J Nutr 112:214-219) pooled analysis of 124 trials: ~9-10% LDL reduction at 2 g/day plant sterols. Effect well-established at biomarker level. ESC/EAS 2025 removed plant sterols from formal cardiovascular recommendations citing absence of outcome trial data — see Phytosterols entry.

Side effects and drug interactions

Common Potential side effects

Generally very well-tolerated.
Mild GI distress (constipation, diarrhea).
May reduce absorption of fat-soluble vitamins (A, D, E, K) and beta-carotene at high doses.
Rare: sitosterolemia — extremely rare genetic disorder (1 in 5 million) where plant sterol supplementation causes severe cardiovascular disease; routine plant sterol supplementation is contraindicated in this rare condition; standard population is unaffected.
Bleeding risk minimal.

Important Drug interactions

Statins — additive cholesterol effect; safe combination; commonly used together.
Ezetimibe — both target intestinal cholesterol absorption; theoretical interaction; consult.
Pravastatin specifically — beta-sitosterol may modestly affect levels.
Fat-soluble vitamins — high-dose plant sterols may reduce absorption; separate by 2-3 hours; consider taking fat-soluble vitamins on different schedule.
Beta-carotene — plant sterols significantly reduce beta-carotene absorption; relevant for those relying on beta-carotene supplementation.
Cholestyramine — additive effects; consult.

Featured in these supplement guides

High Cholesterol→

More Cardiovascular Ingredients

Cardiovascular
Niacin
Niacin (vitamin B3) is an essential water-soluble vitamin central to energy metabolism, DN…
Cardiovascular
Omega-3 Fatty Acids
Omega-3 fatty acids, primarily eicosapentaenoic acid (EPA), docosahexaenoic acid (DHA), an…
Cardiovascular
Potassium
Potassium is the most abundant intracellular cation in the human body and an essential min…
Cardiovascular
Pycnogenol® (French Maritime Pine Bark)
Pycnogenol® (Horphag Research) is a standardized extract from the bark of French maritime…

Frequently asked questions about Beta-Sitosterol

What is beta-sitosterol used for?

Beta-sitosterol is a plant sterol used mainly for two goals: supporting healthy cholesterol (by blocking cholesterol absorption) and easing urinary symptoms of an enlarged prostate (BPH). It is found naturally in nuts, seeds, and vegetable oils.

Does beta-sitosterol help the prostate?

Beta-sitosterol has research for improving urinary flow and symptoms in BPH, sometimes with better symptom data than saw palmetto. It does not shrink the prostate but may ease symptoms. Always have prostate symptoms evaluated by a doctor.

How much beta-sitosterol should I take?

For BPH, studies use around 60 to 130 mg per day of beta-sitosterol, split. For cholesterol, larger plant-sterol intakes (about 2 grams per day of total sterols) are used. Follow product labeling.

Is beta-sitosterol safe?

It is generally well tolerated; mild digestive effects can occur. Like other plant sterols, it can slightly reduce absorption of fat-soluble vitamins. People with the rare condition sitosterolemia should avoid it.

What is Beta-Sitosterol?

Beta-sitosterol is the most abundant plant sterol (phytosterol) in the human diet — structurally similar to cholesterol with an added ethyl group. Found in vegetable oils, nuts, seeds, avocados, whole grains, legumes, and saw palmetto berries.

What is the recommended dosage of Beta-Sitosterol?

The clinically studied dose is BPH: 60-130 mg/day (typically 20 mg three times daily). Cholesterol reduction: 1.5-3 g/day plant sterol blend taken with meals. Take with food for absorption. Always follow the product label and check with a healthcare provider for personal advice.

Is Beta-Sitosterol safe, and does it have side effects?

For most healthy adults, Beta-Sitosterol is well tolerated at studied doses. Reported effects can include: Generally very well-tolerated. Mild GI distress (constipation, diarrhea). It may also interact with some medications. Beta-Sitosterol is not right for everyone, so check with a healthcare provider first if you are pregnant or breastfeeding, have a medical condition, or take prescription medication.

Does Beta-Sitosterol interact with any medications?

Possible interactions include: Statins — additive cholesterol effect; safe combination; commonly used together. Ezetimibe — both target intestinal cholesterol absorption; theoretical interaction; consult. If you take prescription medication, check with a pharmacist or doctor before using it.

How strong is the scientific evidence for Beta-Sitosterol?

NutraSmarts rates the evidence for Beta-Sitosterol as Strong (4 out of 5). It is backed by 4 clinical trials and 4 cited references summarized on this page. A higher rating reflects more, larger, and better-designed human studies.

References(4 citations)

Evidence ratings on NutraSmarts are based on the totality of human clinical research, with emphasis on randomized controlled trials, meta-analyses, and systematic reviews. The references below directly support claims made throughout this page.

  1. Wilt TJ, MacDonald R, Ishani A. beta-sitosterol for the treatment of benign prostatic hyperplasia: a systematic review. BJU Int. 1999;83(9):976-83. doi: 10.1046/j.1464-410x.1999.00026.x.PubMedUsed to support: Primary systematic review for the BPH urinary-symptom claim: pooling RCTs, beta-sitosterol significantly improved International Prostate Symptom Score and urinary flow (increased peak and mean flow rate, reduced residual volume). Key honest caveat stated by the authors: beta-sitosterol did not reduce prostate size, and trials were short-term.
  2. Berges RR, Windeler J, Trampisch HJ, Senge T. Randomised, placebo-controlled, double-blind clinical trial of beta-sitosterol in patients with benign prostatic hyperplasia. Lancet. 1995;345(8964):1529-32. doi: 10.1016/s0140-6736(95)91085-9.PubMedUsed to support: Landmark BPH RCT: in 200 men over 6 months, beta-sitosterol significantly improved the modified Boyarsky symptom score, IPSS and urinary flow versus placebo, but produced no significant change in prostate volume. Confirms symptom/flow benefit without prostate shrinkage.
  3. Berges RR, Kassen A, Senge T. Treatment of symptomatic benign prostatic hyperplasia with beta-sitosterol: an 18-month follow-up. BJU Int. 2000;85(7):842-6. doi: 10.1046/j.1464-410x.2000.00672.x.PubMedUsed to support: Longer-term follow-up of the Lancet RCT cohort: symptom-score and urinary-flow improvements with beta-sitosterol were maintained at 18 months in patients who continued treatment, supporting durability of the lower-urinary-tract-symptom benefit (again without an effect on prostate size).
  4. Ras RT, Geleijnse JM, Trautwein EA. LDL-cholesterol-lowering effect of plant sterols and stanols across different dose ranges: a meta-analysis of randomised controlled studies. Br J Nutr. 2014;112(2):214-9. doi: 10.1017/S0007114514000750.PubMedUsed to support: Supports the cholesterol claim for the wider phytosterol class to which beta-sitosterol belongs: meta-analysis of 124 RCTs showing plant sterols/stanols dose-dependently lower LDL cholesterol (about 9-12 mg/dL at typical ~2 g/day intakes) by reducing intestinal cholesterol absorption. Effect is on LDL via dietary phytosterol intake, not from the low BPH doses.